Index Ventures
Index Ventures is a venture capital firm headquartered in London with offices in San Francisco and Geneva, focused on backing technology-driven startups across Europe, North America, and beyond. The firm specializes in high technology and life sciences, and invests across early and growth stages in sectors such as artificial intelligence, software, data, fintech, healthcare, media, mobility, open source, and security. Since its founding in 1996, Index Ventures has partnered with ambitious entrepreneurs to turn bold ideas into global businesses, providing strategic guidance and capital to help companies scale. Notable portfolio companies include Adyen, Deliveroo, Dropbox, Farfetch, King, Slack, and Supercell, reflecting the firm’s track record of supporting market-changing technology companies.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Geneve
Addex Therapeutics
Series C in 2006
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule drugs that act as allosteric modulators of central nervous system targets, especially G-protein coupled receptors. Based in Geneva, Switzerland, the company aims to address CNS disorders with a platform that may offer advantages over conventional orthosteric therapies. Its lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 for epilepsy and other CNS conditions, and a GABAB positive allosteric modulator for addiction. It collaborates with Janssen Pharmaceuticals to develop mGluR2 PAM compounds. Founded in 2002, Addex operates in Switzerland and Europe, pursuing discovery, development, and potential commercialization of small-molecule therapeutics for CNS disorders.
SpinX
Series B in 2005
SpinX develops and commercializes a programmable lab-on-a-chip platform for applications that ranges from drug discovery to consumer diagnostics. Its products include SpinX Lab, a system to transition from low volume microplate assays to an automated bench-top technology for assays in nanoliter volumes; and workflow, an assay preparation for a panel of enzymatic assays.
Bart Van de Vyver and Piero Zucchelli founded SpinX in 2003. It has its headquarters in Geneva in Switzerland.
Addex Therapeutics
Series B in 2004
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule drugs that act as allosteric modulators of central nervous system targets, especially G-protein coupled receptors. Based in Geneva, Switzerland, the company aims to address CNS disorders with a platform that may offer advantages over conventional orthosteric therapies. Its lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 for epilepsy and other CNS conditions, and a GABAB positive allosteric modulator for addiction. It collaborates with Janssen Pharmaceuticals to develop mGluR2 PAM compounds. Founded in 2002, Addex operates in Switzerland and Europe, pursuing discovery, development, and potential commercialization of small-molecule therapeutics for CNS disorders.
Addex Therapeutics
Series A in 2002
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule drugs that act as allosteric modulators of central nervous system targets, especially G-protein coupled receptors. Based in Geneva, Switzerland, the company aims to address CNS disorders with a platform that may offer advantages over conventional orthosteric therapies. Its lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 for epilepsy and other CNS conditions, and a GABAB positive allosteric modulator for addiction. It collaborates with Janssen Pharmaceuticals to develop mGluR2 PAM compounds. Founded in 2002, Addex operates in Switzerland and Europe, pursuing discovery, development, and potential commercialization of small-molecule therapeutics for CNS disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.